BPCR vs. ATST, ABDN, PHLL, 3IN, JGGI, BPT, RCP, BUR, MNKS, and HVPE
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Alliance Trust (ATST), abrdn (ABDN), Petershill Partners (PHLL), 3i Infrastructure (3IN), JPMorgan Global Growth & Income (JGGI), Bridgepoint Group (BPT), RIT Capital Partners (RCP), Burford Capital (BUR), Monks (MNKS), and HarbourVest Global Private Equity (HVPE). These companies are all part of the "asset management" industry.
BioPharma Credit vs. Its Competitors
Alliance Trust (LON:ATST) and BioPharma Credit (LON:BPCR) are both financial services companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.
Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays an annual dividend of GBX 0.07 per share and has a dividend yield of 7.5%. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 70.1% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.
In the previous week, Alliance Trust's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.
BioPharma Credit has lower revenue, but higher earnings than Alliance Trust. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
Alliance Trust has a net margin of 92.17% compared to BioPharma Credit's net margin of 80.20%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.
Alliance Trust has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.
6.9% of Alliance Trust shares are held by institutional investors. Comparatively, 21.4% of BioPharma Credit shares are held by institutional investors. 2.4% of Alliance Trust shares are held by insiders. Comparatively, 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Alliance Trust beats BioPharma Credit on 8 of the 12 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 9/6/2025 by MarketBeat.com Staff
